Kidney Week

Abstract: SA-PO327

Utilization Trends of Tirzepatide, Glucose-Lowering Medications, and Anti-obesity Medications in Patients with CKD with and without Type 2 Diabetes

Session Information

• Diabetic Kidney Disease: Clinical Pathology, Diagnostic and Treatment Advances
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Diabetic Kidney Disease

• 702 Diabetic Kidney Disease: Clinical

Authors

• Hansrivijit, Panupong, Brigham and Women's Hospital, Boston, Massachusetts, United States

Panupong Hansrivijit, MD

• Ortega-Montiel, Janinne, Brigham and Women's Hospital, Boston, Massachusetts, United States

Janinne Ortega-Montiel, MD, MSc, ScD

• Wexler, Deborah J., Massachusetts General Hospital, Boston, Massachusetts, United States

Deborah J. Wexler, MD, MS

• Patorno, Elisabetta, Brigham and Women's Hospital, Boston, Massachusetts, United States

Elisabetta Patorno, MD, DrPH

• Paik, Julie M., Brigham and Women's Hospital, Boston, Massachusetts, United States

Julie M. Paik, MD, MPH

Background

Tirzepatide was approved by the U.S. FDA in May 2022 for glycemic control in adults with type 2 diabetes (T2D). Our study goal was to describe the utilization of tirzepatide, other glucose-lowering medications (GLM), and anti-obesity medications (AOM) in patients with chronic kidney disease (CKD), regardless of T2D status.

Methods

We obtained data from a large U.S. insurance claims database (Optum) from January 1, 2022, to September 30, 2023. We created two cohorts using validated algorithms based on ICD codes: 1) CKD with T2D and 2) CKD without any diabetes. Incident use of any medications was defined as no prior use in 365 days.

Results

We identified 455,047 patients with CKD and T2D treated with any GLM, and 5,978 patients with CKD without any diabetes treated with any AOM. For patients with CKD and T2D, tirzepatide initiation, regardless of dose, comprised 8.4% of all initiated GLM by the end of September 2023 (Figure 1A). Of 10,661 tirzepatide initiators, the mean age was 65.9 (9.7) years, 42.2% were male, and 64.2% were of white race. For patients with CKD without diabetes, initiation of tirzepatide was second to subcutaneous semaglutide ≤2 mg, with incidence rising from 0.5% in June 2022 to 36.5% of all initiated AOM in December 2022 (Figure 1B). Of 909 tirzepatide initiators, the mean age was 65.4 (10.1) years, 26.2% were male, and 74.4% were of white race.

Conclusion

Tirzepatide use increased over time in patients with CKD. Further studies are needed to assess tirzepatide’s effectiveness and safety compared to other GLM and AOM in patients with CKD.

Figure 1. A) Trends of GLMinitiation in patients with CKD and T2D. B) Trends of AOM initiation in patients with CKD without any diabetes.